ADF00007 Tygon® by Saint Gobain | 1/8" I.D. x 1/4" O.D. x 1/16" Wall | ND-100-65 | Medical/Surgical Tubing | 50' Package Length
Tygon® ND 100-65 tubing, developed by Saint-Gobain, is a state-of-the-art solution for various medical applications, including dialysis, drug delivery, minimally invasive surgery, and more. This tubing stands out for its crystal-clear clarity, ensuring easy fluid flow visualization, a critical feature for medical professionals.
Crafted from a biocompatible polymer, Tygon® ND 100-65 is formulated without DEHP, emphasizing patient safety and environmental responsibility. Its composition exhibits low extractables in soapy and refluxed water, a unique property that enhances its suitability for sensitive medical procedures. Furthermore, this tubing shows excellent blood interaction characteristics, making it ideal for applications involving contact with body fluids.
In compliance with stringent regulatory standards, Tygon® ND 100-65 meets the requirements of Regulation (EC) 1907/2006 (REACH), ensuring it contains no reportable substances or chemicals of concern. It has also been rigorously tested according to various elements of ISO 10993 and USP, including cytotoxicity, hemocompatibility, genotoxicity, and <88> Class VI plastic material, reinforcing its biocompatibility and safety for medical use.
Notably, Tygon® ND 100-65 is free from animal-derived materials, aligning with the ethical and regulatory demands of the medical industry. Its adaptability extends to its bonding and welding capabilities, compatible with heat, electronic (RF)/ultrasonic, solvent, and adhesive methods. This versatility allows for secure and reliable medical devices and systems connections.
Critical applications of Tygon® ND 100-65 include use in minimally invasive devices, blood and IV solutions, dialysis equipment, inhalation equipment, chemotherapy drug delivery systems, kidney dialysis pumps, and peristaltic pumps. Its high surface tension minimizes hold-up volume within the tubing, further enhancing its efficiency and effectiveness in medical procedures.
In summary, Tygon® ND 100-65 tubing represents a fusion of innovative material science and commitment to medical standards, offering an optimal solution for a broad spectrum of healthcare applications where safety, reliability, and clarity are paramount.
- Crystal clear for easy visualization of fluid flow
- Ideal for contact with body fluids
- High surface tension minimizes hold up volume within tubing
- No reportable substances or chemicals of concern for REACH
- Tygon® ND 100-65 has met the criteria of various ISO 10993 and USP tests
- Minimally invasive devices
- Blood and IV solutions
- Dialysis equipment
- Inhalation equipment
- Chemotherapy drug delivery
- Kidney dialysis pumps
- Peristaltic pumps
Related Products
At Liquidyne, we prioritize our commitment to quality and consistency. In 2017 we achieved ISO 9001:2015 Quality Management System certification to ensure we can repeatedly deliver consistently high-quality products and solutions. Being an ISO 9001 facility, together with our USP Class VI Testing, ASME Bioprocessing Equipment (BPE), and EHEDG certification guarantee, we have the methodologies to assure quality. We will quickly and accurately rectify any issues if any of our products are ever in non-conformance.
"Thanks so much! What a quick turn around. It is a pleasure working with Liquidyne."
Process Development Manager
"I received the cart yesterday, thanks for the fast delivery! It feels sturdy. I sat on it. It does not bounce. It is also easy to clean and wipe or wash down."
Vice President, Analytical Development and Manufacturing
"Thanks again for reacting so quickly and meeting me halfway with the element. We will be able to get installed and have things keep moving overnight with the night crew. The little things like this are always greatly appreciated when working with Liquidyne."
Chemical Engineer
“This pump cut our processing time from 3 days to 1 shift. I’m not giving this pump back. You will have to come and get it if you want it... and that won’t likely happen.”
VP Antibody Manufacturing